| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Hemab Therapeutics treibt drei klinische Programme voran - Solide Liquidität bis 2029 | - | Investing.com Deutsch | ||
| 10.11. | Hemab Therapeutics Holdings, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 10.11. | Hemab expects cash to fund operations into 2029 while advancing ~75-patient SOLARA Phase III | 1 | Seeking Alpha | ||
| 10.11. | Hemab Therapeutics Holdings Q3 2026 Earnings Call Transcript | 1 | Benzinga.com | ||
| 10.11. | Hemab Therapeutics Holdings GAAP EPS of -$0.58 misses by $0.06 | 1 | Seeking Alpha | ||
| HEMAB THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 10.11. | Hemab Therapeutics Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 09.11. | Hemab Therapeutics startet Phase-3-Studie für Wirkstoff gegen seltene Blutgerinnungsstörung | 2 | Investing.com Deutsch | ||
| 09.11. | Hemab Therapeutics, Inc.: Hemab Therapeutics Initiates SOLARA, a Pivotal Phase 3 Trial of Sutacimig in Glanzmann Thrombasthenia | 1 | GlobeNewswire (USA) | ||
| 04.11. | Hemab Therapeutics, Inc.: Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition | 6 | GlobeNewswire (USA) | ||
| 15.10. | JPMorgan initiates Hemab Therapeutics stock with overweight rating | 2 | Investing.com | ||
| 12.10. | Rodman & Renshaw startet Coverage für Hemab mit Kaufempfehlung - Therapiepotenzial überzeugt | 3 | Investing.com Deutsch | ||
| 12.10. | Rodman & Renshaw initiates Hemab stock with buy on therapy potential | 1 | Investing.com | ||
| 24.09. | Hemab Therapeutics appoints Keli Walbert to board of directors | 1 | Investing.com | ||
| 24.09. | Hemab Therapeutics, Inc.: Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert | 295 | GlobeNewswire (Europe) | CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment... ► Artikel lesen | |
| 24.09. | Hemab Therapeutics Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.09. | Gubra A/S: Gubra collaboration partner Hemab announces first participant dosed in Phase 1 clinical trial of HMB-003, an investigational therapy for the management of heavy menstrual bleeding | 612 | GlobeNewswire (Europe) | Today, Gubra announced that its partner Hemab Therapeutics has dosed the first healthy volunteer in its Phase 1 clinical trial evaluating HMB-003, an investigational therapy for the management of heavy... ► Artikel lesen | |
| 17.09. | Hemab Therapeutics, Inc.: Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding | 412 | GlobeNewswire (Europe) | Heavy menstrual bleeding is reported in approximately 1 in 3 reproductive-aged women, according to the American College of Obstetricians and Gynecologists, with approximately 23 million seeking care... ► Artikel lesen | |
| 14.08. | Biotech Stocks At 52-Week Highs - Park Dental Partners +10%, Aveanna Healthcare +24%, Candel Therapeutics +10% on Q2 Reports, Labcorp Holdings, Hemab Therapeutics | 1.571 | AFX News | LONDON (dpa-AFX) - The following biotech stocks reached 52-week highs on August 13, 2026, driven by key catalysts such as positive quarterly reports and the issuance of increased guidance figures.Park... ► Artikel lesen | |
| 12.08. | H.C. Wainwright hebt Kursziel für Hemab Therapeutics auf 60 US-Dollar an | 2 | Investing.com Deutsch | ||
| 11.08. | Hemab Therapeutics Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AMGEN | 405,10 | +0,19 % | Argus raises Amgen stock price target on pipeline strength | ||
| BIOGEN | 227,05 | -0,85 % | Biogen Reports Two-Year Data Showing Continued Benefit Of Dianersen In Early Alzheimer's Disease | WESTON (dpa-AFX) - Biogen (BIIB) presented new Phase 2 data showing that diranersen, an investigational therapy targeting the tau protein, continued to slow disease progression in people with... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 864,00 | +0,31 % | Regeneron-Aktie: Erneute Aufwärtsbewegung nach Konsolidierung | Nach den jüngsten Quartalsergebnissen erreichte Regeneron ein neues Jahreshoch, bevor eine Konsolidierung einsetzte. Die anschließende Kurserholung hat ein höheres Tief hinterlassen, während das bisherige... ► Artikel lesen | |
| CELLDEX THERAPEUTICS | 25,520 | +1,59 % | Celldex Therapeutics, Inc.: Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints | Best-in-disease results showed rapid, profound, sustained efficacy, supporting barzolvolimab's potential to be a transformational therapy in CSUEMBARQ-CSU1 and -CSU2 met primary and all key secondary... ► Artikel lesen | |
| ARGENX | 861,40 | +0,14 % | BERNSTEIN RESEARCH stuft Argenx auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat Argenx auf "Outperform" mit einem Kursziel von 914 Euro belassen. Ähnlich wie das Medikament Vygart gegen Autoimmunerkrankungen... ► Artikel lesen | |
| REVOLUTION MEDICINES | 145,20 | -0,31 % | Revolution Medicines' Rasonque gains EC authorisation for pancreatic cancer | ||
| INSMED | 109,58 | +0,37 % | Insmed Inc Q3 Loss Narrows | WASHINGTON (dpa-AFX) - Insmed Inc (INSM) revealed Loss for third quarter of -$100.32 millionThe company's earnings came in at -$100.32 million, or -$0.46 per share. This compares with -$370.02... ► Artikel lesen | |
| ORUKA THERAPEUTICS | 89,00 | +1,71 % | Oruka Therapeutics auf der UBS Biopharma Conference: Wettbewerbsvorteile durch lange Dosierungsintervalle im Fokus | ||
| SUMMIT THERAPEUTICS | 10,500 | 0,00 % | Summit Therapeutics (SMMT) Is Losing Wall Street's Confidence | ||
| KRYSTAL BIOTECH | 269,70 | -6,09 % | Krystal Biotech auf Jefferies-Gesundheitskonferenz: Globale Expansion nimmt Fahrt auf | ||
| ULTRAGENYX | 15,285 | -5,41 % | Ultragenyx auf der Jefferies Global Healthcare Conference: Pfad zur Profitabilität im Fokus | ||
| SCHOLAR ROCK | 43,040 | -1,62 % | Scholar Rock: Solider US-Marktstart für ISEMBYLD - Erstattungsprozesse dämpfen kurzfristigen Umsatzhochlauf | ||
| PALVELLA THERAPEUTICS | 125,00 | -6,72 % | Palvella Therapeutics Inc.: Palvella Therapeutics to Host Webcast to Introduce New QTORIN"Program | ||
| IMMUNOCORE | 24,800 | -0,80 % | Immunocore auf der UBS Global Biopharma Conference: KIMMTRAK treibt Wachstum - Pipeline liefert neue Impulse | ||
| VAXCYTE | 54,00 | +0,93 % | Vaxcyte auf Jefferies Global Healthcare Conference: Zulassungspfad für Erwachsenen-Impfstoff konkretisiert sich |